Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.
Br J Haematol
September 2024
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
This prospective clinical study aimed to evaluate the efficacy and safety of the pre-emptive treatment modality of azacitidine in combination with interferon-α (IFN-α) in AML/MDS patients post-transplantation. Forty-seven patients aged 17-62 were enrolled with 14 patients having completed the planned 12 cycles. Following initiation, 72.
View Article and Find Full Text PDFEssential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Am J Hematol
April 2024
Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Article Synopsis
- Essential thrombocythemia (ET) is a blood disorder caused by mutations in the JAK2 gene, leading to high platelet counts and potential complications like blood clots and transformation into other serious diseases.
- Diagnosis of ET requires confirming high platelet levels while ruling out other similar blood disorders, and bone marrow tests typically show increased megakaryocytes.
- The prognosis for ET patients varies, with median survival around 18 years, but younger patients may live over 35 years, and risk factors for thrombosis depend on age and mutation status.
Depletion of results in age-dependent changes in DNA methylation and gene expression in a zebrafish model of myelodysplastic syndrome.
Front Hematol
September 2023
Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, United States.
Introduction: Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, cytopenias, and dysplasia. The gene encoding ten-eleven translocation 2 (2), a dioxygenase enzyme that catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine, is a recurrently mutated tumor suppressor gene in MDS and other myeloid malignancies. Previously, we reported a stable zebrafish line with a loss-of-function mutation in the gene.
View Article and Find Full Text PDFRUNX1 is required in granulocyte-monocyte progenitors to attenuate inflammatory cytokine production by neutrophils.
Genes Dev
July 2023
Department of Cell and Developmental Biology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA;
The transcription factor RUNX1 is mutated in familial platelet disorder with associated myeloid malignancy (FPDMM) and in sporadic myelodysplastic syndrome and leukemia. RUNX1 was shown to regulate inflammation in multiple cell types. Here we show that RUNX1 is required in granulocyte-monocyte progenitors (GMPs) to epigenetically repress two inflammatory signaling pathways in neutrophils: Toll-like receptor 4 (TLR4) and type I interferon (IFN) signaling.
View Article and Find Full Text PDFTuberculosis-induced aplastic crisis and atypical lymphocyte expansion in advanced myelodysplastic syndrome: A case report and review of literature.
World J Clin Cases
July 2023
Department of Hematology, The Central Hospital of Qingdao West Coast New Area, Qingdao 266555, Shandong Province, China.
Background: Myelodysplastic syndrome (MDS) is caused by malignant proliferation and ineffective hematopoiesis. Oncogenic somatic mutations and increased apoptosis, necroptosis and pyroptosis lead to the accumulation of earlier hematopoietic progenitors and impaired productivity of mature blood cells. An increased percentage of myeloblasts and the presence of unfavorable somatic mutations are signs of leukemic hematopoiesis and indicators of entrance into an advanced stage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!